Bettina M. Cockroft
About Bettina M. Cockroft
Bettina M. Cockroft serves as the Senior Vice President and Chief Medical Officer at Sangamo Therapeutics, Inc. since 2019, bringing extensive experience in clinical research and product development across multiple therapeutic areas.
Work at Sangamo Therapeutics
Bettina M. Cockroft serves as the Senior Vice President and Chief Medical Officer at Sangamo Therapeutics, Inc. since 2019. In this role, she oversees clinical development and medical affairs for the company, which focuses on genomic medicine and innovative therapies. Her leadership contributes to the advancement of therapeutic solutions in various medical fields.
Previous Experience in Clinical Research
Before joining Sangamo Therapeutics, Cockroft held the position of Vice President of Clinical Research in Neurology at Cytokinetics from 2017 to 2019. Prior to that, she was the Head of the Global Clinical Development Unit for Multiple Sclerosis at Merck Serono from 2004 to 2013. Her experience also includes a role as Senior Manager of Clinical Research at Novartis Consumer Health in 2003-2004.
Education and Expertise
Cockroft earned her Doctor of Medicine (MD) degree from Università degli Studi di Genova, graduating Magna cum Laude. She furthered her education with a Master of Business Administration (M.B.A.) from the MIT Sloan School of Management. Her academic background supports her extensive expertise in clinical development and medical strategy.
Multilingual and Global Experience
Bettina M. Cockroft is multilingual, fluent in English, Italian, German, and French. She has lived in four different European countries for over eight years each, in addition to her residence in the United States. This diverse background enhances her ability to manage change and lead multicultural teams effectively.
Board Membership and Professional Interests
Since 2022, Cockroft has been a member of the Board of Directors at Annexon Biosciences. She is open to opportunities for additional Board of Director positions, reflecting her commitment to contributing her medical and strategic insights to the governance of organizations in the healthcare sector.